Recent studies have indicated that autoimmune thrombocytopenic purpura (ATP) patients show immune system alterations that are not restricted to the B-cell compartment, but that also affect T lymphocytes. This report studies the phenotypic characteristics of natural killer (NK) cells in the peripheral blood of ATP patients, as well as their clinical significance in 33 ATP patients with active disease. Ten patients had stable disease (sustained platelet counts > 50,00O/pL without the need for treatment), whereas 23 patients had therapy-dependent disease (platelet counts < 50,00O/pL). A significant increase in both CD56+CD3-NK cells and CD56+CD3+ cytotoxic T lymphocytes was observed in peripheral blood mononuclear cells and in purified CD2+ cells from therapy-dependent ATP patients as compared with ATP patients with stable disease and healthy controls. Moreover, there were more major histocompatibility complex (MHC) class II molecules in the CD56+CD3-cells from the therapy-dependent patients'
HRONIC AUTOIMMUNE thrombocytopenic pur-C pura (ATP) is a disorder caused by an interaction between autoantibodies and the platelet and/or megakaryocyte surface, which provokes their destruction by the reticuloendotelial system.'"
There is increasing evidence that this disease, like other autoimmune diseases, is associated with alterations in the regulation of the immune system f~n c t i o n .~-~ The existence of phenotypic and functional abnormalities in the T-cell compartment of ATP patients has been clearly defined.'-'' However, there is limited information about the characteristics of natural killer (NK) cells in these patients. I2 NK cells are lymphocytes that are functionally defined by their ability to lyse target cells without prior sensitization and without restriction by molecules of the major histocompatibility complex (MHC).'3*'4 These NK cells are morphologically characterized as large granular 1ymph0cytes.l~ However, the expression of surface antigens is heterogeneous in this lymphocyte population and different subsets can be defined. '3,16 
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peripheral blood preparations than there were in the stable ATP patients' and healthy controls' peripheral blood preparations. This growth in the number of CD56+CD3-NK cells was statistically higher in patients whose disease was refractow to conventional therapy (corticosteroids and splenectomy). In addition to the CD56+CD3-NK cells, the percentage of CD3+ T lymphocytes and their proliferative response to phytohemagglutinin (PHA) stimulation were studied in fresh CD2+ preparations from nine patients with stable disease, 22 patients with therapy-dependent disease, and 26 healthy controls. The proliferative response of CD2 + lymphocytes from both groups was similar and significantly defective with respect to that found in healthy controls. In conclusion, clinically severe ATP (therapy-dependent disease) is associated with a significant increase of CD56+CD3-NK cells, which is particularly marked in patients whose disease is refractory to therapy. 0 1993 by The American Society of Hematology.
NK cell "markers" are CD56 and CD16.'7,'8 CD56 appears to identify all of the lymphocytes that possess NK activity, and CD16 (Fc gamma RIII) is also expressed in the majority of NK cell^.'^,'^,'^ The CD56 antigen appears on the surface of already cytotoxic NK cells. These cells also express surface antigens shared with T lymphocytes such as CD2, and heterogeneously they can express other phenotypic markers such as CD57.'6p21 Although CD56 expression is characteristic of lymphoid effectors that kill target cells in an MHC-unrestricted fashion, not all CD56+ cells are typical NK cells. There is a small fraction of T lymphocytes (CD3+ cells) with a less efficient MHC-unrestricted cytotoxic activity that express CD56. This subset coexpresses the CD56 and CD57 antigens, but lacks CD16.'3520.Z2 NK cells have been implicated in several activities in vivo, including destruction of tumor cells, resistence to viral infections, and regulation of both hematopoiesis and B-cell f~nction.'~-'~ In the present study, we investigated the distribution of NK cells and T lymphocyte subsets in fresh peripheral blood mononuclear cells (PBMCs) and in purified CD2+ cells from ATP patients. The clinical significance ofthe phenotypic findings is also studied.
MATERIALS AND METHODS

Put ient Popidat ion
Thirty-three patients (21 women, 12 men; mean age, 50.8 years; range, I I to 8 I ) with clinically active chronic ATP (platelet counts < IOO,OOO/pL) were studied. The diagnosis of ATP was based on the criteria reported by Tsubakio et al": thrombocytopenia for longer than 6 months; increased bone marrow megakaryocytes; absence of splenomegaly; and exclusion of other underlying causes of thrombocytopenia such as connective tissue disease, malignancy, human immunodeficiency virus antibodies, or evidence of other autoimmune disorders. Patients thought to have drug-related thrombocytopenia were also excluded. No patient had clinical evidence of infection at the time of study and none had received any drug with a potential effect on the immune system function during the preceding 3 months. The patients were classified into two groups according to their platelet count and disease course: (1) the first group, defined as the stable disease group, consisted of IO patients with a sustained platelet count greater than 50,00O/pL; (2) the second group, defined as the therapy-dependent ATP group, consisted of 23 patients with a platelet count less than 5O,OOO/pL. The clinical characteristics of the patients according to study group are outlined in Table 1 . Controls consisted of 26 normal age-and sexmatched healthy volunteers with platelet counts greater than 15O,OOO/pL. The number ofperipheral blood lymphocytes wassimilar in ATP patients and healthy controls (not shown). All patients gave informed consent to the experimental protocol.
Treatment and Clinical Study Design
The treatment protocol of the ATP patients studied was as follows: ( I ) Patients who had stable disease did not receive treatment.".'* (2) Patients with a platelet count less than 50,00O/pL received treatment (therapy-dependent ATP). The initial therapy was corticosteroids at doses of 1 mg/kg/d for 3 to 6 weeks. Once normal platelet levels were attained, corticosteroids were tapered off over a 3-to 4-week period. If the platelet count was less than IOO,OOO/pL at 6 weeks, or if there was a relapse, the patients were then either treated with danazol(600 mg/d) for at least 3 months or with splenectomy. In addition, patients who failed to maintain a platelet count greater than 40,000 to 50,00O/pL after splenectomy were also treated with danazol.
The 10 stable ATP patients (patients no. I through IO; seven women, three men; mean age, 53.1 years; range, 20 to 71; median platelet count, 72,000 * 14,OOO/pL) in this group received no treatment at the moment of experimental immunologic protocol (EIP), nor have they received any treatment at the time of writing this report because their disease has remained stable over a mean follow-up period of 39 months (range, 12 to 57). In these 10 patients, the mean interval between diagnosis and EIP was 20 months (range, 6 to 48) ( Table I ). * In these cases. the EIP was performed in PR after corticosteroids and off therapy (all had a platelet count < 50.000/pL before corticosteroid These cases were also analyzed in chronic phase (duration of disease > 6 months) and off therapy, as described in Materials and Methods.
treatment).
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The 23 therapy-dependent ATP patients (no. 11 through 33; 14 women, nine men; mean age, 47.5 years; range, I 1 to 81; median platelet count, 43,000 f 19,00O/pL) can be divided into two separate subgroups depending on when EIP was performed. Eleven patients (no. l l through 2 l ) were evaluated before commencement of specific therapy. In these 1 1 patients, the mean interval between diagnosis and the first EIP was 5.5 months (range, 2 to 12). In six (no. 1 I, 12, 14, 15, 17, and 19) of these 11 patients, the EIP was performed within 6 months of thrombocytopenia (acute phase of the disease). Thus, in these six patients, a second EIP was also performed-after corticosteroid failure or relapse-during the chronic phase of their disease (duration of thrombocytopenia > 6 months). The time from the initial diagnosis of thrombocytopenia to the second EIP ranged from 6 to 17 months, and none of the patients were receiving any immunosuppressive drug for the last 3 months before the second EIP. Twelve patients (no. 22 through 33) were evaluated after receiving some treatment. In these 12 patients, the mean interval between diagnosis of thrombocytopenia and EIP was 34 months (range, 5 to 120). Patient no. 32 was analyzed during both the acute (5 months after diagnosis) and the chronic phase (3 months after corticosteroid failure). Table I shows the treatment received in these 23 therapy-dependent patients before and after EIP.
The EIP was performed twice during the chronic phase of the disease in four stable patients (no. 2, 5, 7, and 9) and eight with therapy-dependent disease (no. 11, 14, 17, 20,26,31,32, and 33).
In patients with therapy-dependent disease, the second EIP was performed off-therapy. The intervals between the two EIPs ranged from 3 months to 8 months.
Outcome of Therapy
We used the following response criteria: complete response (CR), therapy resulted in a platelet count greater than 100,00O/pL; partial response (PR), therapy resulted in a platelet count greater than 50,OOO/ptL; no response (NR), platelet count after therapy remained less than 50,00O/pL. The initial clinical response wasevaluated 6 weeks after initiating corticosteroids, I month after splenectomy, or 3 months after initiating danazol therapy. Six (no. 1 1, 16, 18, 19,22, and 30) of 21 patients achieved an initial CR (28%) after corticosteroids (all relapsed after corticosteroid withdrawal, but they were still able to sustain a stable PR). Five patients (no. 12, 15, 23, 29, and 33) achieved an initial PR (23%) after corticosteroids. The overall initial response (CR and PR) to corticosteroids was similar to that in previous report^.^' Ten patients (no. 14, 17, 20 ,24 through 28,3 1, and 32) had no response to corticosteroids (52%). A low rate of response was observed after splenectomy; four (no. 12, 13, 15, and 29) of the nine splenectomized patients achieved an initial CR (44.4%) and five (no. 14,21, and 26 through 28) had NR (55.6%). Patient age and duration ofdisease were similar in splenectomy-responding and splenectomy-nonresponding patients. Danazol treatment resulted in an initial PR in five (no. 14, 17,2 1,24, and 25) of nine (55.6%) patients. Four patients (no. 23, and 26 through 28) had NR to danazol therapy (44.4%) ( Table 1) .
EIP
Cell isolation. Fresh peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll-Hypaque (Lymphoprep Nyegaard, Oslo, Norway) gradient centrifugation and resuspended in RPMI I640 (Microbiological Associates, Walkersville, MD) containing 10% heat-inactivated fetal calf serum (GIBCO, NY). Fresh CD2+ cells were purified by double-rosetting with sheep red blood cells (SRBC) pretreated with 2-aminoiethylisothio-uronium bromide (AET) as previously de~cribed.'~ The purity of phenotypically defined CD2+ lymphocytes in the rosetted cellular preparations was 94% k 2.8% for the ATP group and 95.5% f 1.7% for the control group. After counting, cells were resuspended in RPMI 1640 containing 10% fetal calf serum, L-glutamine (2 mmol/L; Flow Laboratories, Irvine, UK), HEPES (0.5%, Flow Laboratories), and 1% penicillin-streptomycin (Difco Laboratories, Detroit, MI). This will be referred to as complete medium. Cell preparation viability was always greater than 95%.
Staining of cells and FACS analysis. The immunofluorescence studies were performed on purified CD2+ lymphocyte preparations. In indicated cases, simultaneous studies with PBMCs were also performed. Expression of membrane antigens was analyzed using the two-or three-color combination of fluorescein isothiocyanate (FITC), phycoerythrin (PE), and PerCP (in three-color analysis)-labeled monoclonal antibodies (MoAbs). The following twocolor combinations were used in the study (FITC/PE): CD3/CD2, CD3/CD19, CD3/CD56, CD3/CD16, CD57/CD3, CD3/CDI Ib, CD16/CD56, CD16/CD1 Ib, CD57/CD56, DR/CD56, and CD45/ CD14. In addition, CD3 MoAb was used as a third color (PerCP) in some experiments. Control studies comprising unstained cells and cells incubated with isotype-matched irrelevant FITC, PE-and PerCP-labeled MoAbs were performed with each experiment. All MoAbs were obtained from Becton Dickinson (Mountain View, CA). The specificities of these reagents, subclasses, and CD designations are summarized in Table 2 .
Acquisition and analysis for either two-or three-color immunofluorescence procedures were performed with a FACSCAN flow cytometer using Lysis I1 software (Becton Dickinson). For each combination of MoAbs, 10,000 fresh and viable lymphocytes were acquired and data were stored in list-mode files. An electronic gate drawn around the lymphocyte population, as defined by forward scatter (FSC) and side scatter characteristics (SSC), and single histogram plots were examined to determine the percentage of positive cells for a single antigen. Contour graphs of FLl versus FL2 were examined for dual-antigen expression and the proportions of FLI+FL2-, FLl+FL2+, FLI-FL2+, and FLI-FL2-subpopulations determined using quadrant statistics. 2 t 2 (7) Results are expressed as the mean percentage r SD with P values determined by the Mann-Whitney U-test. Number of patients and controls is shown in parentheses. Pvalues are given when statistically significant. P < .05 compared with healthy controls. t P < .01 compared with healthy controls. t P < .05 compared with stable ATP patients.
Prolifeation studies. Fresh CD2+ lymphocytes (50,000 cells/ well) were cultured in complete medium on 96-well flat-bottom culture plates in the presence or absence of phytohemagglutinin (PHA, 10 pg/mL; Difco Laboratories). This reagent was tested in dose-response titrations before use. Cultures were incubated at 37°C in a humidified atmosphere containing 5% C02 for 5 days. 
Statistical Analysis
To analyze the results, the unpaired Mann-Whitney U-test and Pearson's correlation analysis were used. A P value less than .05 was considered significant.
RESULTS
NK Cells and Non-MHC-Restricted Cytotoxic T Lymphocytes in ATP Patients
To obtain an enriched preparation of T lymphocytes and NK cells from ATP patients with stable disease, from patients with therapy-dependent disease, and from healthy controls, CD2+ cells were purified and the expression of CD3 and CD56 antigens analyzed (Table 3 ). There were no significant differences in the percentage of total CD2+ cells present in lymphocyte preparations from either group of ATP patients as compared with the percentage found in healthy controls. However, the percentage of CD3+ T lymphocytes was significantly decreased in the CD2+ preparations from therapy-dependent ATP patients with respect to that found in healthy controls (P < .05). We did not observe significant differences between the percentage of CD3+ lymphocytes present in the cellular preparations from either group of ATP patients. The percentage of CD56+CD3-NK cells was significantly increased in the purified CD2+ lymphocyte preparations from therapy-dependent ATP patients with respect to that of stable ATP patients and healthy controls (P < .OS and P < .01, respectively). Additional two-color cytofluorometric analysis showed a significantly increased percentage of CD 16+CD3-, CD57+CD3-, and CDI 1 b+CD3-cells in CD2+ preparations from therapy-dependent ATP patients with respect to that found in stable ATP patients and healthy controls (Table 3) ( P < .05).
We also analyzed the expression of the CD56 antigen on the surface of the CD3+ T lymphocytes. As shown in Table  3 , there was also a significant increase in the percentage of CD56+CD3+ T lymphocytes in purified CD2+ preparations from therapy-dependent ATP patients with respect to that found in stable disease patients and healthy controls ( P < .OS). The percentages of CD16+CD3+, CD57+CD3', and CD 1 1 b+CD3+ were similar in both groups of ATP patients and in healthy controls.
The cellular distribution of CD2+ lymphocyte preparations was studied in seven patients twice, in the acute and in the chronic phase. Similar percentages in the expression of the studied antigens (CD2, CD3, CD56, CD16, and CD57) in the purified CD2' lymphocyte preparations were found in both phases of the disease (data not shown).
To rule out the possibility that this increased expression of NK-associated antigens was a consequence of a selection of this population by the CD2+ lymphocyte purification procedure, we investigated the expression of NK-associated antigens on PBMCs from ATP patients and healthy controls. A significant increase in both CD56+CD3-NK cells and CD56+CD3+ T lymphocytes in PBMCs from therapydependent ATP patients with respect to levels found in ATP patients with stable disease and in healthy controls was also observed (Table 4) ( P < .05).
Class 11 Molecules of MHC on NK Cells From ATP Patients
We analyzed the expression of activation antigens on CD56+CD3-NK cells from ATP patients. As shown in Ta 
Proliferative Response in CD2+ Cellular Preparations From ATP Patients
A defective proliferative response of PBMCs or purified CD2+ lymphocyte preparations to mitogenic signals has been described in patients with clinically active ATP, although a marked variability between patients was also observed.'-" The proliferative response to PHA by CD2+ lymphocytes from nine patients with stable disease and 22 patients with therapy-dependent disease and 26 healthy controls was studied. We observed that the proliferative response of CD2+ lymphocytes from patients with stable and therapy-dependent disease was significantly decreased with respect to that found in healthy controls ( P > .001). There were no significant differences between the proliferative responses of CD2+ lymphocytes from both groups of ATP patients (Fig 2) ( P > .05 ).
There was no statistically significant correlation between the proliferative response of CD2+ lymphocytes and the percentage of CD56+CD3-cells present in the cellular preparations in either the entire group of patients ( P > .05; correlation coefficient, 0.22) or in each group individually analyzed ( P > .05; correlation coefficients, 0.16 for stable ATP patients and -0.29 for therapy-dependent ATP patients). Nor were there significant differences between the percentage of CD 14 monocytes in the cellular preparations from either group of patients (stable ATP, 1.7% t 0.8%; therapy-dependent ATP, 2% f 1.1%; P > .05) and healthy controls (1.9% f 1.3%: P > .05).
NK Cells in ATP: Correlation With Treatment Outcome
We analyzed the phenotypic characteristics of the purified CD2+ lymphocytes from therapy-dependent ATP patients as a function of the patients' clinical response to therapy (Table 6 ). We observed that the percentage of CD56+CD3-NK cells in those patients with PR or NR after therapy with corticosteroids or splenectomy was significantly enhanced with respect to those who responded (CR) to these therapeutic modalities ( P < .05). No significant differences were found between the percentage of CD56+CD3+ T lymphocytes in ATP patients with a clinical response or in nonresponders to corticosteroids or splenectomy. We also found that danazol-treated patients, all of whom were nonresponding patients (PR or NR), had a percentage of CD56+CD3-NK cells and CD56+CD3+ T lym- The expression of DR molecules is increased in CD56+CD3-NK cells from therapy-dependent ATP patients. Patterns of CD3 and CD56 expression (A and C) in purified CD2+ preparations were analyzed; next, the CD56+CD3-NK cell subset was gated (gate R1) and its DR expression examined (Band D) in preparations from a representative therapy-dependent ATP patient (A and B) and a healthy control (C and D) using a three-color immunofluorescence procedure as described in Materials and Methods. For personal use only. on October 25, 2017. by guest www.bloodjournal.org From phocytes similar to that found in nonresponding (PR or NR) patients to corticosteroids or splenectomy (P > .05).
Because the EIP was performed before initiating the specific therapy in some therapy-dependent ATP patients, and in others it was performed after initiating therapy, there is a risk of some selection bias. To rule out this possibility, we analyzed the phenotypic characteristics and treatment outcome in those therapy-dependent ATP patients in whom an EIP was performed before starting treatment (no. 11 through 21). The percentage of CD56+CD3-NK cells in seven (no. 11 through 13, 15, 16, 18 , and 19) of these 1 1 patients reached the range found in healthy controls (10% f 3% and 9% f 7%, respectively). These seven therapy-dependent patients subsequently responded to conventional therapy (corticosteroids or splenectomy). The other four patients (no. 14, 17, 20, and 21) who showed a significantly increased percentage of CD56+CD3-NK cells (3 1% f 9%) with respect to therapy-responding patients and healthy controls were nonresponding (PR or NR) patients ( P < .05). Whether they responded to therapy or not, in the I 1 patients who had EIP evaluation before starting treatment, the percentage of CD56+CD3+ was not significantly different from that found in the healthy controls (data not shown) (P > .05).
Finally, we also analyzed the level of serum immunoglobulins in ATP patients. No correlation between their serum level and percentage of NK cells was observed (not shown).
DISCUSSION
In this work, we have demonstrated that therapy-dependent ATP (defined as thrombocytopenia < 50,OOO/pL) is associated to an expansion of the CD56TD3-NK cell and CD56+CD3+ cytotoxic T subsets. There is also phenotypic evidence of in vivo activation of these NK cells in the therapy-dependent ATP patients. This increase in the percentage of NK cells was particularly marked in patients whose disease was refractory to therapy.
There is a previous report of normal amounts of NK cells that were nevertheless functionally defective in peripheral blood from ATP patients.12 This apparent contradiction with our results can be explained by the referred work having studied a small number of patients, most of whom had only a mild degree of thrombocytopenia, which means that they probably had a stable form of the disease. In our group of patients with a similar clinical situation, we did not find a significant increase of NK cells in peripheral blood.
The mechanism by which the CD56TD3-NK cell subset is increased in therapy-dependent ATP patients is unknown. However, secondary indtiction of this lymphocyte subset by the platelet destruction can be ruled out, since it has not been found in patients with secondary autoimmune thrombocytopenic purpura from systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).'* It is possible to suggest that this CD56+CD3-NK cell expansion is a manifestation of the structural and/or functional abnormal immune system of these patients. In this sense, several phenotypic and functional alterations have been described in the T-cell compartment of these patients.'-" The selective finding of CD56+CD3-NK cell expansion in severe ATP patients (platelet counts < 50,OOO/pL) can be explained by the immunologic heterogeneity of this disease.34 However, this enhancement of the CD56+CD3+ NK compartment found in peripheral blood from patients with severe ATP might also represent the progression of the underlying minimal immunologic alterations associated with stable disease.
The clinical significance of this expansion of CD56'-CD3-NK cells in therapy-dependent ATP patients has been analyzed. It is clear that those patients who do not respond to conventional therapy (corticosteroids and splenectomy) showed a significantly increased percentage of CD56+CD3-NK cells in peripheral blood in comparison to the percentage found in responding (CR) patients. Thus, there is a clear association between the severity and therapeutic refractoriness of the disease in ATP patients and the expansion of CD56+CD3-NK cells in their peripheral blood.
IgG antibodies are known to be involved in the increased destruction of platelets in the majority of ATP patient^.^^^^^ The clinical association between the expansion of the CD3TD56+ NK cells and the severity of ATP could imply a pathogenic role of these NK cells in platelet destruction. The CD16 antigen (Fc gamma RIII) expressed by NK cells may participate in the NK cell-triggering that occurs in antibody-dependent cellular cytotoxicity (ADCC).37 Activation through CD16 results in the expression of activation antigens and the secretion of c y t~k i n e s ,~~.~~ and can ultiFor personal use only. on October 25, 2017. by guest www.bloodjournal.org From mately trigger NK cells to kill IgG-coated targets. In this sense, we have also observed that the expanded CD56+CD3-NK cell subset in severe ATP patients displays a high expression of MHC class I1 molecules, suggesting that these cases with increased CD56TD3-NK cells are in vivo-activated.
There is increasing evidence that ATP patients show a marked immune system alteration that is not restricted to B lymphocytes, but also involves the T-lymphocyte and NK cell compartment^.'-'^ In this sense, there is also evidence of abnormalities in both the NK and T lymphocyte compartments in different autoimmune diseases in which a pathogenic role for the autoantibodies produced by B-cell compartment is ~u s p e c t e d .~~' A significant proportion of cases with persistent NK-associated expansions are known to have a history of autoimmune disorders such as neutropenia:* seropositive RA, and Felty' syndrome. 43 In the observed hypoproliferative response by CD2+ lymphocytes from either stable or therapy-dependent ATP patients to a polyclonal mitogen, different cellular alterations may be involved. There may have been an intrinsic defective proliferative response by the CD3+ T lymphocytes and/ or an inhibitory effect of CD56+CD3-NK cells on the blastogenic response of T lymphocytes. This second explanation is unlikely, since the patients with stable disease, whose percentage of CD56+CD3-NK cells present in the CD2+ lymphocyte preparations was similar to that in the healthy controls, showed a defective proliferative response to PHA. Furthermore, we have not found a statistically significant correlation between the proliferative response by the CD2+ lymphocyte preparations and the percentage of CD56+CD3-NK cells in ATP patients.
Further studies are needed to define the mechanism of production and the pathogenic role of this enhancement of CD56TD3-NK cells in patients with severe ATP.
